Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.82 |
| ▸ | HRH2 | P25021 | 4/20 | 0.77 |
| ▸ | HRH1 | P35367 | 4/20 | 0.77 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.63 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 7/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227297 | 0.98 | HRH3 (0.85) | HRH3HRH2HRH1PSMB1PSMB5 | |
| SCHEMBL1714312 | 0.93 | HRH3 (0.71) | HRH3HRH2HRH1KCNA5 | |
| SCHEMBL491845 | 0.92 | HRH3 (0.97) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL5855947 | 0.90 | HRH3 (0.94) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL492096 | 0.90 | HRH3 (1.00) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL491825 | 0.90 | HRH3 (1.00) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL5276568 | 0.90 | HRH3 (1.00) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL491835 | 0.89 | HRH3 (1.00) | HRH3HRH2HRH1 | |
| SCHEMBL5856351 | 0.89 | HRH3 (0.97) | HRH3HRH2HRH1CACNA1B | |
| SCHEMBL5623066 | 0.88 | HRH3 (0.79) | HRH3HRH2HRH1KCNA5CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288382-B2 | Diaminothiazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110092502-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7879856-B2 | 5-(quinoxalin-2-yl)-N2-(3,4,5-trimethoxyphenyl)thiazole-2,4-diamine; useful in inhibiting the activity of the receptor protein tyrosine kinase Axl; rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| US-20080227789-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NOVARTIS AG (CH) | 2006-04-27 | — | — | US | disclosed |
| EP-1597243-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072050-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092502-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | HRH3 931/4885HRH2 964/4885HRH1 1334/4885 |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NCOR1, NCOR2, NR4A1 | HRH3 526/4885HRH2 978/4885HRH1 830/4885 |
| US-20080227789-A1 | DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | HRH3 931/4885HRH2 964/4885HRH1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.